Friday, December 12, 2008

Breast Cancer - AstraZeneca's Response To Letrozole Datapresented At San Antonio Breast Cancer Symposium (SABCS), 11 -14 December 2008

AstraZeneca is pleased to see additional data presented at SABCS reinforce that there is no evidence that a sequencing strategy is superior to a 5 year aromatase inhibitor (AIs) strategy. AstraZeneca believes that AIs should be used upfront in all newly diagnosed breast cancer postmenopausal women as it is critical to keep patients cancer free for as long as possible. Complete news at...

Dr. Samir Hanash, Program Head at the Fred Hutchinson Cancer Research Center in Seattle, WA will give the keynote address on the discovery and development of biomarkers at the 2nd annual Oncology Biomarkers Conference on January 19-20, 2009 in Miami, Florida. Dr. Complete news at...

Intercell AG (VSE: ICLL) announced the execution of a contract modification with the U.S. Department of Health and Human Services (HHS). The agreement commits additional funding of USD 12.5 m for Intercell's Pandemic Influenza program. Intercell is developing a Pandemic Influenza Vaccine Patch System that includes an immunostimulant patch administered in conjunction with an injected Pandemic Influenza vaccine (manufactured by Solvay Biologicals, B.V. Complete news at...

In a new tactic in the fight against cancer, Cornell University researcher Michael King has developed what he calls a lethal "lint brush" for the blood -- a tiny, implantable device that captures and kills cancer cells in the bloodstream before they spread through the body. Complete news at...

Vical Incorporated (Nasdaq: VICL) announced that the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial. The company previously reported that the vaccines had achieved potentially protective levels of antibody responses in up to 67% of evaluable subjects in the trial's higher dose cohorts. Complete news at...

Douglas Easton, Ph.D., whose international studies in breast cancer explained the genetic patterns and causes of the BRCA1 and BRCA2 gene mutations which indicate a person's risk for breast cancer, has been selected to receive the inaugural American Association for Cancer Research (AACR) Outstanding Investigator Award in Breast Cancer Research. This award, funded by Susan G. Complete news at...

The Truth About Using Drugs to Cure Osteoporosis

If nothing is done, bone problems could get worse and turn into agonizing and unbearable bone problems causing confinement or worse. This essay looks for answers to some key questions concerning the use of drugs in treating bone problems. People experience a reduction in mineral density in their bones, as a result either because of the normal wear of age, or as a result of lack of calcium. In its more advanced stage, this decline in bone density is described as Osteoporosis, where the bones become porous and fracture easily.

Are Physicians Overusing An Invasive Cardiac Treatment?

Researchers are asking if cardiology patients receive intervention-type treatments, such as stents, too often and too quickly.

In regions of the country where cardiologists perform high numbers of cardiac catheterizations to diagnose heart problems, patients may be receiving a treatment known as percutaneous cardiac intervention (PCI) more than they need or want, according to a study published online this week in the journal Circulation. The study will also be in the journal's December 16/23 print edition.

read more

More at...

New data released today demonstrate that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

read more

More at...

The American Academy of Orthopaedic Surgeons (AAOS) has approved and released an evidence-based clinical practice guideline on "Treatment of Osteoarthritis of the Knee". These guidelines were explicitly developed to include only treatments which are less invasive than knee replacement surgery. While a wide range of treatment options are available, they should always be tailored to individual patients after discussions with their physicians.

The Guidelines and Evidence Report recommends:

read more

More at...